Prostate cancer is the second most commonly occurring cancer in men and the fourth most commonly occurring cancer overall. There were 1.3 million new cases of prostate cancer in 2018.1 Siemens Healthineers offers a full menu of Prostate Specific Antigen (PSA) tests that aid in the detection, monitoring and management of prostate cancer. In addition to traditional PSA tests, the Siemens Healthineers portfolio includes the unique Complexed PSA assay that is an alternative to conventional testing and can improve the detection of clinically significant cancers.
PSA testing is a classic screening method to aid in the detection of prostate cancer and is clinically accepted by the NACB and EGTM for both detection and monitoring.2 Siemens Healthineers offers the following PSA assays:
PSA Assay: Intended for the measurement of serum PSA, in conjunction with a digital rectal exam (DRE), as an aid in the detection of prostate cancer in men aged 50 years and older. This assay is further indicated as an aid in the management (monitoring) of patients with prostate cancer.
Free PSA (fPSA) Assay: Intended to be used in conjunction with the Atellica® IM PSA Assay in men aged 50 years or older with total PSA values between 4 and 10 ng/mL and a digital rectal exam (DRE) non‑suspicious for cancer to determine the percent free PSA value. The percent free PSA value can be used as an aid in discriminating between prostate cancer and benign prostatic disease.
Complexed PSA (cPSA) Assay: Intended for the measurement of serum‑complexed PSA in conjunction with digital rectal exam (DRE) as an aid in the detection of prostate cancer in men aged 50 years or older. PSA complexed with alpha-1-antichymotrypsin (ACT) comprises a higher proportion of PSA in men with prostate cancer.3-5 This assay is further indicated as an aid in the management (monitoring) of prostate cancer patients.
Siemens Healthineers PSA Assay Benefits
- Reduce unnecessary biopsies by using an assay that helps to discriminate between prostate cancer and benign prostatic diseases.5-7
- Achieve accurate results with improved specificity in the detection of prostate cancer.4,5,7
- Improve patient management with information on possible disease relapse.
PSA system availability: Atellica® IM Analyzer, ADVIA Centaur® CP/ XP/XPT Immunoassay systems, Dimension Vista® Systems, and IMMULITE® 2000/2000 XPi Immunoassay System.
fPSA system availability: Atellica® IM Analyzer, ADVIA Centaur® XP/XPT Immunoassay systems, Dimension Vista® Systems, and IMMULITE® 2000/2000 XPi Immunoassay System.
cPSA system availability: Atellica® IM Analyzer and ADVIA Centaur® CP/ XP/XPT Immunoassay systems
1Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, in press.
2NACB Laboratory Medicine Practice Guidelines. Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast and Ovarian Cancers. 2009.
3Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek D J,Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol. 2000 Nov;164(5):1671-2.
4Lilja H, Christensson A, Dahlen U, et al. Prostate-specific antigen in human serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;37(9):1618–1625.
5Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6.
6Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542-7.
7Lilja H. Significance of different molecular forms of serum PSA. Urol Clin North Am.1993;20(4):681–686.
82016-10-25 E PN 781452.001.